Cargando…
Antibodies in the Diagnosis, Prognosis, and Prediction of Psychotic Disorders
Blood-based biomarker discovery for psychotic disorders has yet to impact upon routine clinical practice. In physical disorders antibodies have established roles as diagnostic, prognostic and predictive (theranostic) biomarkers, particularly in disorders thought to have a substantial autoimmune or i...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6293207/ https://www.ncbi.nlm.nih.gov/pubmed/29474698 http://dx.doi.org/10.1093/schbul/sby021 |
_version_ | 1783380506981695488 |
---|---|
author | Pollak, Thomas A Rogers, Jonathan P Nagele, Robert G Peakman, Mark Stone, James M David, Anthony S McGuire, Philip |
author_facet | Pollak, Thomas A Rogers, Jonathan P Nagele, Robert G Peakman, Mark Stone, James M David, Anthony S McGuire, Philip |
author_sort | Pollak, Thomas A |
collection | PubMed |
description | Blood-based biomarker discovery for psychotic disorders has yet to impact upon routine clinical practice. In physical disorders antibodies have established roles as diagnostic, prognostic and predictive (theranostic) biomarkers, particularly in disorders thought to have a substantial autoimmune or infective aetiology. Two approaches to antibody biomarker identification are distinguished: a “top-down” approach, in which antibodies to specific antigens are sought based on the known function of the antigen and its putative role in the disorder, and emerging “bottom-up” or “omics” approaches that are agnostic as to the significance of any one antigen, using high-throughput arrays to identify distinctive components of the antibody repertoire. Here we review the evidence for antibodies (to self-antigens as well as infectious organism and dietary antigens) as biomarkers of diagnosis, prognosis, and treatment response in psychotic disorders. Neuronal autoantibodies have current, and increasing, clinical utility in the diagnosis of organic or atypical psychosis syndromes. Antibodies to selected infectious agents show some promise in predicting cognitive impairment and possibly other symptom domains (eg, suicidality) within psychotic disorders. Finally, infectious antibodies and neuronal and other autoantibodies have recently emerged as potential biomarkers of response to anti-infective therapies, immunotherapies, or other novel therapeutic strategies in psychotic disorders, and have a clear role in stratifying patients for future clinical trials. As in nonpsychiatric disorders, combining biomarkers and large-scale use of “bottom-up” approaches to biomarker identification are likely to maximize the eventual clinical utility of antibody biomarkers in psychotic disorders. |
format | Online Article Text |
id | pubmed-6293207 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-62932072018-12-19 Antibodies in the Diagnosis, Prognosis, and Prediction of Psychotic Disorders Pollak, Thomas A Rogers, Jonathan P Nagele, Robert G Peakman, Mark Stone, James M David, Anthony S McGuire, Philip Schizophr Bull Regular Articles Blood-based biomarker discovery for psychotic disorders has yet to impact upon routine clinical practice. In physical disorders antibodies have established roles as diagnostic, prognostic and predictive (theranostic) biomarkers, particularly in disorders thought to have a substantial autoimmune or infective aetiology. Two approaches to antibody biomarker identification are distinguished: a “top-down” approach, in which antibodies to specific antigens are sought based on the known function of the antigen and its putative role in the disorder, and emerging “bottom-up” or “omics” approaches that are agnostic as to the significance of any one antigen, using high-throughput arrays to identify distinctive components of the antibody repertoire. Here we review the evidence for antibodies (to self-antigens as well as infectious organism and dietary antigens) as biomarkers of diagnosis, prognosis, and treatment response in psychotic disorders. Neuronal autoantibodies have current, and increasing, clinical utility in the diagnosis of organic or atypical psychosis syndromes. Antibodies to selected infectious agents show some promise in predicting cognitive impairment and possibly other symptom domains (eg, suicidality) within psychotic disorders. Finally, infectious antibodies and neuronal and other autoantibodies have recently emerged as potential biomarkers of response to anti-infective therapies, immunotherapies, or other novel therapeutic strategies in psychotic disorders, and have a clear role in stratifying patients for future clinical trials. As in nonpsychiatric disorders, combining biomarkers and large-scale use of “bottom-up” approaches to biomarker identification are likely to maximize the eventual clinical utility of antibody biomarkers in psychotic disorders. Oxford University Press 2019-01 2018-02-21 /pmc/articles/PMC6293207/ /pubmed/29474698 http://dx.doi.org/10.1093/schbul/sby021 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Regular Articles Pollak, Thomas A Rogers, Jonathan P Nagele, Robert G Peakman, Mark Stone, James M David, Anthony S McGuire, Philip Antibodies in the Diagnosis, Prognosis, and Prediction of Psychotic Disorders |
title | Antibodies in the Diagnosis, Prognosis, and Prediction of Psychotic Disorders |
title_full | Antibodies in the Diagnosis, Prognosis, and Prediction of Psychotic Disorders |
title_fullStr | Antibodies in the Diagnosis, Prognosis, and Prediction of Psychotic Disorders |
title_full_unstemmed | Antibodies in the Diagnosis, Prognosis, and Prediction of Psychotic Disorders |
title_short | Antibodies in the Diagnosis, Prognosis, and Prediction of Psychotic Disorders |
title_sort | antibodies in the diagnosis, prognosis, and prediction of psychotic disorders |
topic | Regular Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6293207/ https://www.ncbi.nlm.nih.gov/pubmed/29474698 http://dx.doi.org/10.1093/schbul/sby021 |
work_keys_str_mv | AT pollakthomasa antibodiesinthediagnosisprognosisandpredictionofpsychoticdisorders AT rogersjonathanp antibodiesinthediagnosisprognosisandpredictionofpsychoticdisorders AT nagelerobertg antibodiesinthediagnosisprognosisandpredictionofpsychoticdisorders AT peakmanmark antibodiesinthediagnosisprognosisandpredictionofpsychoticdisorders AT stonejamesm antibodiesinthediagnosisprognosisandpredictionofpsychoticdisorders AT davidanthonys antibodiesinthediagnosisprognosisandpredictionofpsychoticdisorders AT mcguirephilip antibodiesinthediagnosisprognosisandpredictionofpsychoticdisorders |